Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
Amazon Launches Infrastructure Region in New Zealand
AWS Asia Pacific (New Zealand) Region gives customers more choice to run…
IMG Shares 2025 Autumn Travel Trends: Top Destinations and Increased Spending
IMG took a sample of its customers and reviewed more than 30,000…
IBM Report: 13% Of Organizations Reported Breaches Of AI Models Or Applications, 97% Of Which Reported Lacking Proper AI Access Controls
U.S. breach costs rise to $10.22 million, despite the global average cost…
ASM announces completion of share buyback program
Almere, The NetherlandsJuly 28, 2025, 5:45 p.m. CET ASM International N.V. (Euronext…
Kia Announces 2025 Second Quarter Business Results
Kia posts record quarterly revenue of KRW 29.35 trillion in Q2, up…
Tirupati, India, Among Asia’s Most Affordable Summer Destinations in 2025: Agoda
Digital travel platform Agoda has revealed its list of the most budget-friendly…
World-Leading Breakthrough! Risen Energy’s HJT Modules Hit Average 740Wp Mass Production with Record 26.61% Cell Efficiency
NINGBO, China, July 3, 2025 /PRNewswire/ -- A milestone in global heterojunction (HJT)…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…
XRP mining launches new application: available to users around the world
Los Angeles, California , June 20, 2025 (GLOBE NEWSWIRE) -- As the…